At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 38 enrolled

Drug / intervention

ocriplasmin +4 moredrug

Likely dose

ocriplasmin 125µgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01159665

NCT01159665Phase 2Completed

Compare CT.gov

An Open-Label, Ascending-Exposure-Time, Single Center Trial to Evaluate the Pharmacokinetic Properties of Ocriplasmin (Generic Name of the Molecule Microplasmin) Intravitreal Injection in Subjects Scheduled for Primary Pars Plana Vitrectomy

ThromboGenics·interventional·Posted Jul 9, 2010·Updated Dec 17, 2014

In Brief

A Phase 2 clinical trial evaluating ocriplasmin for Vitrectomy. Completed, enrolled 38 participants across 1 site.

Detailed Summary

To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 µg dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV)

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsVitrectomy

CountriesBelgium

Collaborators--

Timeline

Phase 2CompletedFinished

2011201220132014201520162017201820192020202120222023202420252026

Enrollment StartJul 2010

First PostedJul 2010

Primary CompletionNov 2010

Study CompletionJan 2011

TodayJul 2026

First PostedJul 9, 2010

Enrollment StartJul 1, 2010

Primary CompletionNov 1, 2010

Study CompletionJan 1, 2011

TodayJul 2, 2026

Enrollment to primary: 4 monthsPosted 16.0 years ago